The Ras/MAPK pathway and hepatocarcinoma: Pathogenesis and therapeutic implications

European Journal of Clinical Investigation

Volumn 45, Issue 6, 2015, Pages 609-623

  Delire, Bénédicte ^a   Stärkel, Peter ^a,b  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^b CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

Author keywords

Hepatocarcinogenesis; Human; Liver cancer; Ras dysregulation; Ras inhibitors; Ras signaling

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; BINIMETINIB; COBIMETINIB; LONAFARNIB; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE PHOSPHATASE 1; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; PIMASERTIB; RAF PROTEIN; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A; RAS PROTEIN; REFAMETINIB; REGORAFENIB; SALIRASIB; SELUMETINIB; SORAFENIB; SPROUTY PROTEIN; SPROUTY RELATED PROTEIN EVH1 DOMAIN CONTAINING PROTEIN; TIPIFARNIB; TRAMETINIB; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; GUANOSINE TRIPHOSPHATASE ACTIVATING PROTEIN; MEMBRANE PROTEIN; MONOMERIC GUANINE NUCLEOTIDE BINDING PROTEIN; NICOTINAMIDE; PROTEIN KINASE INHIBITOR; RASSF1 PROTEIN, HUMAN; RASSF5 PROTEIN, HUMAN; SIGNAL PEPTIDE; SPRED1 PROTEIN, HUMAN; TUMOR SUPPRESSOR PROTEIN;

ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; CELL CYCLE PROGRESSION; CELL DIFFERENTIATION; CELL GROWTH; CELL MIGRATION; CELL MOTILITY; CELL PROLIFERATION; CELL SURVIVAL; DOWN REGULATION; ENZYME INHIBITION; EPIGENETICS; GENE MUTATION; HETEROZYGOSITY LOSS; HUMAN; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION; TUMOR GROWTH; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; CARCINOGENESIS; CARCINOMA, HEPATOCELLULAR; GENETICS; LIVER NEOPLASMS; METABOLISM; MOUSE; MUTATION; PHYSIOLOGY; RAT;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOGENESIS; CARCINOMA, HEPATOCELLULAR; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LIVER NEOPLASMS; MAP KINASE SIGNALING SYSTEM; MEMBRANE PROTEINS; MICE; MITOGEN-ACTIVATED PROTEIN KINASES; MONOMERIC GTP-BINDING PROTEINS; MUTATION; NIACINAMIDE; PHENYLUREA COMPOUNDS; PROTEIN KINASE INHIBITORS; RAF KINASES; RAS GTPASE-ACTIVATING PROTEINS; RAS PROTEINS; RATS; TUMOR SUPPRESSOR PROTEINS;

EID: 84929501731     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/eci.12441     Document Type: Review

References (133)

1. Nordenstedt H, White DL, El-Serag HB. The changing pattern of epidemiology in hepatocellular carcinoma. Dig Liver Dis 2010;42(Suppl 3):S206-14.
2. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007;132:2557-76.
3. Bruix J, Boix L, Sala M, Llovet JM. Focus on hepatocellular carcinoma. Cancer Cell 2004;5:215-9.
4. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012;56:908-43.
5. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-90.
6. Zender L, Villanueva A, Tovar V, Sia D, Chiang DY, Llovet JM. Cancer gene discovery in hepatocellular carcinoma. J Hepatol 2010;52:921-9.
7. Llovet JM, Bruix J. Molecular targeted therapies in hepatocellular carcinoma. Hepatology 2008;48:1312-27.
8. Aravalli RN, Cressman EN, Steer CJ. Cellular and molecular mechanisms of hepatocellular carcinoma: an update. Arch Toxicol 2013;87:227-47.
9. Ito Y, Sasaki Y, Horimoto M, Wada S, Tanaka Y, Kasahara A et al. Activation of mitogen-activated protein kinases/extracellular signal-regulated kinases in human hepatocellular carcinoma. Hepatology 1998;27:951-8.
10. Calvisi DF, Ladu S, Gorden A, Farina M, Conner EA, Lee JS et al. Ubiquitous activation of Ras and Jak/Stat pathways in human HCC. Gastroenterology 2006;130:1117-28.
11. Schmidt CM, McKillop IH, Cahill PA, Sitzmann JV. Increased MAPK expression and activity in primary human hepatocellular carcinoma. Biochem Biophys Res Commun 1997;236:54-8.
12. Zhang X, Zhang H, Ye L. Effects of hepatitis B virus X protein on the development of liver cancer. J Lab Clin Med 2006;147:58-66.
13. Nakamura H, Aoki H, Hino O, Moriyama M. HCV core protein promotes heparin binding EGF-like growth factor expression and activates Akt. Hepatol Res 2011;41:455-62.
14. Carlomagno F, Chiariello M. Growth factor transduction pathways: paradigm of anti-neoplastic targeted therapy. J Mol Med (Berl) 2014;92:723-33.
15. Turjanski AG, Vaque JP, Gutkind JS. MAP kinases and the control of nuclear events. Oncogene 2007;26:3240-53.
16. Ohrnberger S, Thavamani A, Braeuning A, Lipka DB, Kirilov M, Geffers R et al. Dysregulated serum response factor triggers formation of hepatocellular carcinoma. Hepatology 2015;61:979-89.
17. Osaki LH, Gama P. MAPKs and signal transduction in the control of gastrointestinal epithelial cell proliferation and differentiation. Int J Mol Sci 2013;14:10143-61.
18. Schubbert S, Bollag G, Shannon K. Deregulated Ras signaling in developmental disorders: new tricks for an old dog. Curr Opin Genet Dev 2007;17:15-22.
19. Rajalingam K, Schreck R, Rapp UR, Albert S. Ras oncogenes and their downstream targets. Biochim Biophys Acta 2007;1773:1177-95.
20. Dhillon AS, Hagan S, Rath O, Kolch W. MAP kinase signalling pathways in cancer. Oncogene 2007;26:3279-90.
21. Cox AD, Der CJ. Ras history: the saga continues. Small GTPases 2010;1:2-27.
22. Cox AD, Der CJ. The dark side of Ras: regulation of apoptosis. Oncogene 2003;22:8999-9006.
23. Volodko N, Gordon M, Salla M, Ghazaleh HA, Baksh S. RASSF tumor suppressor gene family: biological functions and regulation. FEBS Lett 2014;588:2671-84.
24. Yeung K, Janosch P, McFerran B, Rose DW, Mischak H, Sedivy JM et al. Mechanism of suppression of the Raf/MEK/extracellular signal-regulated kinase pathway by the raf kinase inhibitor protein. Mol Cell Biol 2000;20:3079-85.
25. Engelhardt CM, Bundschu K, Messerschmitt M, Renne T, Walter U, Reinhard M et al. Expression and subcellular localization of Spred proteins in mouse and human tissues. Histochem Cell Biol 2004;122:527-38.
26. Lee SA, Ladu S, Evert M, Dombrowski F, De Murtas V, Chen X et al. Synergistic role of Sprouty2 inactivation and c-Met up-regulation in mouse and human hepatocarcinogenesis. Hepatology 2010;52:506-17.
27. Calvisi DF, Pinna F, Meloni F, Ladu S, Pellegrino R, Sini M et al. Dual-specificity phosphatase 1 ubiquitination in extracellular signal-regulated kinase-mediated control of growth in human hepatocellular carcinoma. Cancer Res 2008;68:4192-200.
28. Herrmann C. Ras-effector interactions: after one decade. Curr Opin Struct Biol 2003;13:122-9.
29. Shaw RJ, Cantley LC. Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 2006;441:424-30.
30. Charette N, Vandeputte C, Starkel P. Ras in digestive oncology: from molecular biology to clinical implications. Curr Opin Oncol 2014;26:454-61.
31. Min L, He B, Hui L. Mitogen-activated protein kinases in hepatocellular carcinoma development. Semin Cancer Biol 2011;21:10-20.
32. Huynh H, Nguyen TT, Chow KH, Tan PH, Soo KC, Tran E. Over-expression of the mitogen-activated protein kinase (MAPK) kinase (MEK)-MAPK in hepatocellular carcinoma: its role in tumor progression and apoptosis. BMC Gastroenterol 2003;3:19.
33. Tsuboi Y, Ichida T, Sugitani S, Genda T, Inayoshi J, Takamura M et al. Overexpression of extracellular signal-regulated protein kinase and its correlation with proliferation in human hepatocellular carcinoma. Liver Int 2004;24:432-6.
34. McKillop IH, Schmidt CM, Cahill PA, Sitzmann JV. Altered expression of mitogen-activated protein kinases in a rat model of experimental hepatocellular carcinoma. Hepatology 1997;26:1484-91.
35. Klein PJ, Schmidt CM, Wiesenauer CA, Choi JN, Gage EA, Yip-Schneider MT et al. The effects of a novel MEK inhibitor PD184161 on MEK-ERK signaling and growth in human liver cancer. Neoplasia 2006;8:1-8.
36. Chen L, Shi Y, Jiang CY, Wei LX, Wang YL, Dai GH. Expression and prognostic role of pan-Ras, Raf-1, pMEK1 and pERK1/2 in patients with hepatocellular carcinoma. Eur J Surg Oncol 2011;37:513-20.
37. Calvisi DF, Ladu S, Conner EA, Seo D, Hsieh JT, Factor VM et al. Inactivation of Ras GTPase-activating proteins promotes unrestrained activity of wild-type Ras in human liver cancer. J Hepatol 2011;54:311-9.
38. Fernandez-Medarde A, Santos E. Ras in cancer and developmental diseases. Genes Cancer 2011;2:344-58.
39. Grisham JW. Interspecies comparison of liver carcinogenesis: implications for cancer risk assessment. Carcinogenesis 1997;18:59-81.
40. Taketomi A, Shirabe K, Muto J, Yoshiya S, Motomura T, Mano Y et al. A rare point mutation in the Ras oncogene in hepatocellular carcinoma. Surg Today 2013;43:289-92.
41. Buchmann A, Bauer-Hofmann R, Mahr J, Drinkwater NR, Luz A, Schwarz M. Mutational activation of the c-Ha-ras gene in liver tumors of different rodent strains: correlation with susceptibility to hepatocarcinogenesis. Proc Natl Acad Sci USA 1991;88:911-5.
42. Maronpot RR, Fox T, Malarkey DE, Goldsworthy TL. Mutations in the ras proto-oncogene: clues to etiology and molecular pathogenesis of mouse liver tumors. Toxicology 1995;101:125-56.
43. Harada N, Oshima H, Katoh M, Tamai Y, Oshima M, Taketo MM. Hepatocarcinogenesis in mice with beta-catenin and Ha-ras gene mutations. Cancer Res 2004;64:48-54.
44. McMahon G, Davis EF, Huber LJ, Kim Y, Wogan GN. Characterization of c-Ki-ras and N-ras oncogenes in aflatoxin B1-induced rat liver tumors. Proc Natl Acad Sci USA 1990;87:1104-8.
45. Weihrauch M, Benicke M, Lehnert G, Wittekind C, Wrbitzky R, Tannapfel A. Frequent k- ras -2 mutations and p16(INK4A)methylation in hepatocellular carcinomas in workers exposed to vinyl chloride. Br J Cancer 2001;84:982-9.
46. Froment O, Boivin S, Barbin A, Bancel B, Trepo C, Marion MJ. Mutagenesis of ras proto-oncogenes in rat liver tumors induced by vinyl chloride. Cancer Res 1994;54:5340-5.
47. Boivin-Angele S, Lefrancois L, Froment O, Spiethoff A, Bogdanffy MS, Wegener K et al. Ras gene mutations in vinyl chloride-induced liver tumours are carcinogen-specific but vary with cell type and species. Int J Cancer 2000;85:223-7.
48. Maertens O, Cichowski K. An expanding role for RAS GTPase activating proteins (RAS GAPs) in cancer. Adv Biol Regul 2014;55:1-14.
49. Jin H, Wang X, Ying J, Wong AH, Cui Y, Srivastava G et al. Epigenetic silencing of a Ca(2+)-regulated Ras GTPase-activating protein RASAL defines a new mechanism of Ras activation in human cancers. Proc Natl Acad Sci USA 2007;104:12353-8.
50. Vigil D, Cherfils J, Rossman KL, Der CJ. Ras superfamily GEFs and GAPs: validated and tractable targets for cancer therapy? Nat Rev Cancer 2010;10:842-57.
51. Qiu GH, Xie H, Wheelhouse N, Harrison D, Chen GG, Salto-Tellez M et al. Differential expression of hDAB2IPA and hDAB2IPB in normal tissues and promoter methylation of hDAB2IPA in hepatocellular carcinoma. J Hepatol 2007;46:655-63.
52. Zhang X, Li N, Li X, Zhao W, Qiao Y, Liang L et al. Low expression of DAB2IP contributes to malignant development and poor prognosis in hepatocellular carcinoma. J Gastroenterol Hepatol 2012;27:1117-25.
53. Schmidt VA, Chiariello CS, Capilla E, Miller F, Bahou WF. Development of hepatocellular carcinoma in Iqgap2-deficient mice is IQGAP1 dependent. Mol Cell Biol 2008;28:1489-502.
54. White CD, Khurana H, Gnatenko DV, Li Z, Odze RD, Sacks DB et al. IQGAP1 and IQGAP2 are reciprocally altered in hepatocellular carcinoma. BMC Gastroenterol 2010;10:125.
55. Donninger H, Clark JA, Monaghan MK, Schmidt ML, Vos M, Clark GJ. Cell cycle restriction is more important than apoptosis induction for RASSF1A protein tumor suppression. J Biol Chem 2014;289:31287-95.
56. Hesson L, Dallol A, Minna JD, Maher ER, Latif F. NORE1A, a homologue of RASSF1A tumour suppressor gene is inactivated in human cancers. Oncogene 2003;22:947-54.
57. Moshnikova A, Frye J, Shay JW, Minna JD, Khokhlatchev AV. The growth and tumor suppressor NORE1A is a cytoskeletal protein that suppresses growth by inhibition of the ERK pathway. J Biol Chem 2006;281:8143-52.
58. Di GS, Bianchi P, Destro A, Grizzi F, Malesci A, Laghi L et al. Quantitative evaluation of RASSF1A methylation in the non-lesional, regenerative and neoplastic liver. BMC Cancer 2006;6:89.
59. Gao W, Kondo Y, Shen L, Shimizu Y, Sano T, Yamao K et al. Variable DNA methylation patterns associated with progression of disease in hepatocellular carcinomas. Carcinogenesis 2008;29:1901-10.
60. Hu L, Chen G, Yu H, Qiu X. Clinicopathological significance of RASSF1A reduced expression and hypermethylation in hepatocellular carcinoma. Hepatol Int 2010;4:423-32.
61. Schagdarsurengin U, Wilkens L, Steinemann D, Flemming P, Kreipe HH, Pfeifer GP et al. Frequent epigenetic inactivation of the RASSF1A gene in hepatocellular carcinoma. Oncogene 2003;22:1866-71.
62. Yu J, Ni M, Xu J, Zhang H, Gao B, Gu J et al. Methylation profiling of twenty promoter-CpG islands of genes which may contribute to hepatocellular carcinogenesis. BMC Cancer 2002;2:29.
63. Calvisi DF, Evert M, Dombrowski F. Pathogenetic and Prognostic Significance of Inactivation of RASSF Proteins in Human Hepatocellular Carcinoma. Mol Biol Int 2012;2012:849874.
64. Zhang YJ, Wu HC, Shen J, Ahsan H, Tsai WY, Yang HI et al. Predicting hepatocellular carcinoma by detection of aberrant promoter methylation in serum DNA. Clin Cancer Res 2007;13:2378-84.
65. Macheiner D, Heller G, Kappel S, Bichler C, Stattner S, Ziegler B et al. NORE1B, a candidate tumor suppressor, is epigenetically silenced in human hepatocellular carcinoma. J Hepatol 2006;45:81-9.
66. Calvisi DF, Ladu S, Gorden A, Farina M, Lee JS, Conner EA et al. Mechanistic and prognostic significance of aberrant methylation in the molecular pathogenesis of human hepatocellular carcinoma. J Clin Invest 2007;117:2713-22.
67. Ren J, He W, Zhang R, Li Z, Cao W, Yao J et al. RASSF2A promoter methylation in hepatitis B virus-related hepatocellular carcinogenesis and its correlation with elevated serum alpha-fetoprotein level. J Huazhong Univ Sci Technolog Med Sci 2009;29:309-12.
68. Yoshida T, Hisamoto T, Akiba J, Koga H, Nakamura K, Tokunaga Y et al. Spreds, inhibitors of the Ras/ERK signal transduction, are dysregulated in human hepatocellular carcinoma and linked to the malignant phenotype of tumors. Oncogene 2006;25:6056-66.
69. Ma XN, Liu XY, Yang YF, Xiao FJ, Li QF, Yan J et al. Regulation of human hepatocellular carcinoma cells by Spred2 and correlative studies on its mechanism. Biochem Biophys Res Commun 2011;410:803-8.
70. Frey MR, Carraro G, Batra RK, Polk DB, Warburton D. Sprouty keeps bowel kinases regular in colon cancer, while miR-21 targets Sprouty. Cancer Biol Ther 2011;11:122-4.
71. Masoumi-Moghaddam S, Amini A, Morris DL. The developing story of Sprouty and cancer. Cancer Metastasis Rev 2014;33:695-720.
72. Sirivatanauksorn Y, Sirivatanauksorn V, Srisawat C, Khongmanee A, Tongkham C. Differential expression of sprouty genes in hepatocellular carcinoma. J Surg Oncol 2012;105:273-6.
73. Fong CW, Chua MS, McKie AB, Ling SH, Mason V, Li R et al. Sprouty 2, an inhibitor of mitogen-activated protein kinase signaling, is down-regulated in hepatocellular carcinoma. Cancer Res 2006;66:2048-58.
74. Lee SA, Ho C, Roy R, Kosinski C, Patil MA, Tward AD et al. Integration of genomic analysis and in vivo transfection to identify sprouty 2 as a candidate tumor suppressor in liver cancer. Hepatology 2008;47:1200-10.
75. Wang C, Delogu S, Ho C, Lee SA, Gui B, Jiang L et al. Inactivation of Spry2 accelerates AKT-driven hepatocarcinogenesis via activation of MAPK and PKM2 pathways. J Hepatol 2012;57:577-83.
76. Tannapfel A, Sommerer F, Benicke M, Katalinic A, Uhlmann D, Witzigmann H et al. Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma. Gut 2003;52:706-12.
77. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S et al. Mutations of the BRAF gene in human cancer. Nature 2002;417:949-54.
78. Buchmann A, Karcier Z, Schmid B, Strathmann J, Schwarz M. Differential selection for B-raf and Ha-ras mutated liver tumors in mice with high and low susceptibility to hepatocarcinogenesis. Mutat Res 2008;638:66-74.
79. Jaworski M, Buchmann A, Bauer P, Riess O, Schwarz M. B-raf and Ha-ras mutations in chemically induced mouse liver tumors. Oncogene 2005;24:1290-5.
80. Colombino M, Sperlongano P, Izzo F, Tatangelo F, Botti G, Lombardi A et al. BRAF and PIK3CA genes are somatically mutated in hepatocellular carcinoma among patients from South Italy. Cell Death Dis 2012 ;3:e259.
81. Hwang YH, Choi JY, Kim S, Chung ES, Kim T, Koh SS et al. Over-expression of c-raf-1 proto-oncogene in liver cirrhosis and hepatocellular carcinoma. Hepatol Res 2004;29:113-21.
82. Kalkuhl A, Troppmair J, Buchmann A, Stinchcombe S, Buenemann CL, Rapp UR et al. p21Ras downstream effectors are increased in activity or expression in mouse liver tumors but do not differ between ras-mutated and ras-wild-type lesions. Hepatology 1998;27:1081-8.
83. Walker EJ, Rosenberg SA, Wands JR, Kim M. Role of Raf Kinase Inhibitor Protein in Hepatocellular Carcinoma. For Immunopathol Dis Therap 2011;2:195-204.
84. Lee HC, Tian B, Sedivy JM, Wands JR, Kim M. Loss of Raf kinase inhibitor protein promotes cell proliferation and migration of human hepatoma cells. Gastroenterology 2006;131:1208-17.
85. Schuierer MM, Bataille F, Weiss TS, Hellerbrand C, Bosserhoff AK. Raf kinase inhibitor protein is downregulated in hepatocellular carcinoma. Oncol Rep 2006;16:451-6.
86. Fremin C, Meloche S. From basic research to clinical development of MEK1/2 inhibitors for cancer therapy. J Hematol Oncol 2010;3:8.
87. Hoshino R, Chatani Y, Yamori T, Tsuruo T, Oka H, Yoshida O et al. Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors. Oncogene 1999;18:813-22.
88. Fremin C, Ezan F, Boisselier P, Bessard A, Pages G, Pouyssegur J et al. ERK2 but not ERK1 plays a key role in hepatocyte replication: an RNAi-mediated ERK2 knockdown approach in wild-type and ERK1 null hepatocytes. Hepatology 2007;45:1035-45.
89. Bessard A, Fremin C, Ezan F, Fautrel A, Gailhouste L, Baffet G. RNAi-mediated ERK2 knockdown inhibits growth of tumor cells in vitro and in vivo. Oncogene 2008;27:5315-25.
90. Gailhouste L, Ezan F, Bessard A, Fremin C, Rageul J, Langouet S et al. RNAi-mediated MEK1 knock-down prevents ERK1/2 activation and abolishes human hepatocarcinoma growth in vitro and in vivo. Int J Cancer 2010;126:1367-77.
91. Caja L, Sancho P, Bertran E, Iglesias-Serret D, Gil J, Fabregat I. Overactivation of the MEK/ERK pathway in liver tumor cells confers resistance to TGF-{beta}-induced cell death through impairing up-regulation of the NADPH oxidase NOX4. Cancer Res 2009;69:7595-602.
92. Guegan JP, Fremin C, Baffet G. The MAPK MEK1/2-ERK1/2 Pathway and Its Implication in Hepatocyte Cell Cycle Control. Int J Hepatol 2012;2012:328372.
93. Honma N, Genda T, Matsuda Y, Yamagiwa S, Takamura M, Ichida T et al. MEK/ERK signaling is a critical mediator for integrin-induced cell scattering in highly metastatic hepatocellular carcinoma cells. Lab Invest 2006;86:687-96.
94. Lin YW, Chuang SM, Yang JL. ERK1/2 achieves sustained activation by stimulating MAPK phosphatase-1 degradation via the ubiquitin-proteasome pathway. J Biol Chem 2003;278:21534-41.
95. Calvisi DF, Pinna F, Pellegrino R, Sanna V, Sini M, Daino L et al. Ras-driven proliferation and apoptosis signaling during rat liver carcinogenesis is under genetic control. Int J Cancer 2008;123:2057-64.
96. Feo F, Frau M, Tomasi ML, Brozzetti S, Pascale RM. Genetic and epigenetic control of molecular alterations in hepatocellular carcinoma. Exp Biol Med (Maywood) 2009;234:726-36.
97. Ezzeldin M, Borrego-Diaz E, Taha M, Esfandyari T, Wise AL, Peng W et al. RalA signaling pathway as a therapeutic target in hepatocellular carcinoma (HCC). Mol Oncol 2014;8:1043-53.
98. Ding Y, Chen B, Wang S, Zhao L, Chen J, Ding Y et al. Overexpression of Tiam1 in hepatocellular carcinomas predicts poor prognosis of HCC patients. Int J Cancer 2009;124:653-8.
99. Huang J, Ye X, Guan J, Chen B, Li Q, Zheng X et al. Tiam1 is associated with hepatocellular carcinoma metastasis. Int J Cancer 2013;132:90-100.
100. Aksamitiene E, Kiyatkin A, Kholodenko BN. Cross-talk between mitogenic Ras/MAPK and survival PI3K/Akt pathways: a fine balance. Biochem Soc Trans 2012;40:139-46.
101. Wang C, Cigliano A, Delogu S, Armbruster J, Dombrowski F, Evert M et al. Functional crosstalk between AKT/mTOR and Ras/MAPK pathways in hepatocarcinogenesis: implications for the treatment of human liver cancer. Cell Cycle 2013;12:1999-2010.
102. Gotzmann J, Huber H, Thallinger C, Wolschek M, Jansen B, Schulte-Hermann R et al. Hepatocytes convert to a fibroblastoid phenotype through the cooperation of TGF-beta1 and Ha-Ras: steps towards invasiveness. J Cell Sci 2002;115:1189-202.
103. Janda E, Lehmann K, Killisch I, Jechlinger M, Herzig M, Downward J et al. Ras and TGF[beta] cooperatively regulate epithelial cell plasticity and metastasis: dissection of Ras signaling pathways. J Cell Biol 2002;156:299-313.
104. Thiery JP. Epithelial-mesenchymal transitions in development and pathologies. Curr Opin Cell Biol 2003;15:740-6.
105. Zucchini-Pascal N, Peyre L, Rahmani R. Crosstalk between beta-catenin and snail in the induction of epithelial to mesenchymal transition in hepatocarcinoma: role of the ERK1/2 pathway. Int J Mol Sci 2013;14:20768-92.
106. Liu L, Cao Y, Chen C, Zhang X, McNabola A, Wilkie D et al. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res 2006;66:11851-8.
107. Chappell WH, Steelman LS, Long JM, Kempf RC, Abrams SL, Franklin RA et al. Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health. Oncotarget 2011;2:135-64.
108. Cervello M, McCubrey JA, Cusimano A, Lampiasi N, Azzolina A, Montalto G. Targeted therapy for hepatocellular carcinoma: novel agents on the horizon. Oncotarget. 2012;3:236-60.
109. Schneider-Merck T, Borbath I, Charette N, De SC, Abarca J, Leclercq I et al. The Ras inhibitor farnesylthiosalicyclic acid (FTS) prevents nodule formation and development of preneoplastic foci of altered hepatocytes in rats. Eur J Cancer 2009;45:2050-60.
110. Starkel P, Charette N, Borbath I, Schneider-Merck T, De SC, Abarca J et al. Ras inhibition in hepatocarcinoma by S-trans-trans-farnesylthiosalicyclic acid: association of its tumor preventive effect with cell proliferation, cell cycle events, and angiogenesis. Mol Carcinog 2012;51:816-25.
111. Charette N, De SC, Lannoy V, Horsmans Y, Leclercq I, Starkel P. Salirasib inhibits the growth of hepatocarcinoma cell lines in vitro and tumor growth in vivo through ras and mTOR inhibition. Mol Cancer 2010;9:256.
112. Charette N, De SC, Horsmans Y, Leclercq I, Starkel P. Salirasib sensitizes hepatocarcinoma cells to TRAIL-induced apoptosis through DR5 and survivin-dependent mechanisms. Cell Death Dis 2013;4:e471.
113. El-Nassan HB. Recent progress in the identification of BRAF inhibitors as anti-cancer agents. Eur J Med Chem 2014;72:170-205.
114. Carr BI, Cavallini A, Lippolis C, D'Alessandro R, Messa C, Refolo MG et al. Fluoro-Sorafenib (Regorafenib) effects on hepatoma cells: growth inhibition, quiescence, and recovery. J Cell Physiol 2013;228:292-7.
115. D'Alessandro R, Refolo MG, Lippolis C, Messa C, Cavallini A, Rossi R et al. Reversibility of regorafenib effects in hepatocellular carcinoma cells. Cancer Chemother Pharmacol 2013;72:869-77.
116. Wilhelm SM, Dumas J, Adnane L, Lynch M, Carter CA, Schutz G et al. Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int J Cancer 2011;129:245-55.
117. Ravi S, Singal AK. Regorafenib: an evidence-based review of its potential in patients with advanced liver cancer. Core Evid 2014;9:81-7.
118. Shen YC, Lin ZZ, Hsu CH, Hsu C, Shao YY, Cheng AL. Clinical trials in hepatocellular carcinoma: an update. Liver Cancer 2013;2:345-64.
119. Neuzillet C, Tijeras-Raballand A, de Mestier L, Cros J, Faivre S, Raymond E. MEK in cancer and cancer therapy. Pharmacol Ther 2014;141:160-71.
120. Huynh H, Soo KC, Chow PK, Tran E. Targeted inhibition of the extracellular signal-regulated kinase kinase pathway with AZD6244 (ARRY-142886) in the treatment of hepatocellular carcinoma. Mol Cancer Ther 2007;6:138-46.
121. Schmieder R, Puehler F, Neuhaus R, Kissel M, Adjei AA, Miner JN et al. Allosteric MEK1/2 inhibitor refametinib (BAY 86-9766) in combination with sorafenib exhibits antitumor activity in preclinical murine and rat models of hepatocellular carcinoma. Neoplasia 2013;15:1161-71.
122. O'Neil BH, Goff LW, Kauh JS, Strosberg JR, Bekaii-Saab TS, Lee RM et al. Phase II study of the mitogen-activated protein kinase 1/2 inhibitor selumetinib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2011;29:2350-6.
123. Huynh H, Chow PK, Soo KC. AZD6244 and doxorubicin induce growth suppression and apoptosis in mouse models of hepatocellular carcinoma. Mol Cancer Ther 2007;6:2468-76.
124. Huynh H. AZD6244 (ARRY-142886) enhances the antitumor activity of rapamycin in mouse models of human hepatocellular carcinoma. Cancer 2010;116:1315-25.
125. Huynh H, Ngo VC, Koong HN, Poon D, Choo SP, Toh HC et al. AZD6244 enhances the anti-tumor activity of sorafenib in ectopic and orthotopic models of human hepatocellular carcinoma (HCC). J Hepatol 2010;52:79-87.
126. Shin JW, Chung YH. Molecular targeted therapy for hepatocellular carcinoma: current and future. World J Gastroenterol 2013;19:6144-55.
127. Galuppo R, Ramaiah D, Ponte OM, Gedaly R. Molecular therapies in hepatocellular carcinoma: what can we target? Dig Dis Sci 2014;59:1688-97.
128. Chan SL, Yeo W. Targeted therapy of hepatocellular carcinoma: present and future. J Gastroenterol Hepatol 2012;27:862-72.
129. Lachenmayer A, Alsinet C, Chang CY, Llovet JM. Molecular approaches to treatment of hepatocellular carcinoma. Dig Liver Dis 2010;42(Suppl 3):S264-72.
130. Venturelli S, Armeanu S, Pathil A, Hsieh CJ, Weiss TS, Vonthein R et al. Epigenetic combination therapy as a tumor-selective treatment approach for hepatocellular carcinoma. Cancer 2007;109:2132-41.
131. Ahn EY, Kim JS, Kim GJ, Park YN. RASSF1A-mediated regulation of AREG via the Hippo pathway in hepatocellular carcinoma. Mol Cancer Res 2013;11:748-58.
132. Qiu X, Zhang L, Lu S, Song Y, Lao Y, Hu J, Fan H. Upregulation of DNMT1 mediated by HBx suppresses RASSF1A expression independent of DNA methylation. Oncol Rep 2014;31:202-8.
133. Liu LL, Zhang MF, Pan YH, Yun JP, Zhang CZ. NORE1A sensitises cancer cells to sorafenib-induced apoptosis and indicates hepatocellular carcinoma prognosis. Tumour Biol 2014;35:1763-74.